CL2019000221A1 - Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. - Google Patents

Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.

Info

Publication number
CL2019000221A1
CL2019000221A1 CL2019000221A CL2019000221A CL2019000221A1 CL 2019000221 A1 CL2019000221 A1 CL 2019000221A1 CL 2019000221 A CL2019000221 A CL 2019000221A CL 2019000221 A CL2019000221 A CL 2019000221A CL 2019000221 A1 CL2019000221 A1 CL 2019000221A1
Authority
CL
Chile
Prior art keywords
thiazolo
substituted compounds
pyridine substituted
malt1 inhibitors
malt1
Prior art date
Application number
CL2019000221A
Other languages
English (en)
Inventor
Gagan Kukreja
Nageswara Rao Irlapati
Arun Rangnath Jagdale
Gokul Keruji Deshmukh
Vinod Popatrao Vyavahare
Kiran Chandrashekhar Kulkarni
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CL2019000221A1 publication Critical patent/CL2019000221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE FÓRMULA GENERAL (I), EN LA QUE R1-R3 SON COMO SE DEFINEN EN EL PRESENTE DOCUMENTO, PARA SU USO COMO INHIBIDORES DE MALT1 EN EL TRATAMIENTO DE ENFERMEDADES O TRASTORNOS AUTOINMUNES E INFLAMATORIOS. TAMBIÉN SE DESCRIBEN MÉTODOS PARA SINTETIZAR LOS COMPUESTOS. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN UN COMPUESTO DE LA INVENCIÓN Y UN MÉTODO PARA TRATAR UN PACIENTE POR UNA ENFERMEDAD O TRASTORNO AUTOINMUNE O INFLAMATORIO, POR EJEMPLO, UN CÁNCER, ADMINISTRANDO UN COMPUESTO DE LA INVENCIÓN.
CL2019000221A 2016-07-29 2019-01-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. CL2019000221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29

Publications (1)

Publication Number Publication Date
CL2019000221A1 true CL2019000221A1 (es) 2019-06-07

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000221A CL2019000221A1 (es) 2016-07-29 2019-01-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.

Country Status (15)

Country Link
US (1) US20190275012A9 (es)
JP (1) JP2019522035A (es)
KR (1) KR20190033607A (es)
CN (1) CN110312724A (es)
AU (1) AU2017302182B2 (es)
CA (1) CA3032334A1 (es)
CL (1) CL2019000221A1 (es)
DO (1) DOP2019000020A (es)
IL (1) IL289474A (es)
MX (1) MX2019001132A (es)
PE (1) PE20190656A1 (es)
PH (1) PH12019500214A1 (es)
RU (1) RU2019104890A (es)
SG (1) SG11201900745VA (es)
WO (1) WO2018020474A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
WO2018165385A1 (en) 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
WO2019099307A1 (en) * 2017-11-17 2019-05-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
AU2018395291A1 (en) 2017-12-28 2020-07-30 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
AU2019289222B2 (en) * 2018-06-18 2023-07-13 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
EP3810609B1 (en) * 2018-06-18 2024-06-12 Janssen Pharmaceutica NV Pyrazole derivatives as malt1 inhibitors
CN109265453A (zh) * 2018-10-23 2019-01-25 华侨大学 一种用作caspase-3激活剂的缩氨基脲类衍生物及其应用
TWI848400B (zh) 2018-11-28 2024-07-11 日商武田藥品工業股份有限公司 雜環化合物及醫藥
EP3953345B1 (en) * 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
WO2021063735A1 (en) * 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods for using them
WO2021241611A1 (ja) 2020-05-27 2021-12-02 武田薬品工業株式会社 複素環化合物の製造方法
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
JP7818011B2 (ja) * 2020-10-16 2026-02-19 レラファイド バイオサイエンシーズ， インコーポレイテッド Ｍａｌｔ１モジュレーターおよびその使用
WO2022101676A1 (en) * 2020-11-12 2022-05-19 Monopteros Therapeutics,Inc. Materials and methods of treating cancer
CN118451068A (zh) 2021-12-30 2024-08-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用
CN116535424B (zh) * 2022-01-26 2025-04-11 武汉誉祥医药科技有限公司 作为malt1抑制剂的三并环化合物及其药物组合物和应用
EP4473966A4 (en) 2022-02-02 2026-01-21 Ono Pharmaceutical Co CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT
EP4472734A1 (en) 2022-02-03 2024-12-11 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
ES3064783T3 (en) * 2022-03-31 2026-04-29 Rarefied Biosciences Inc Malt1 modulators and uses thereof
EP4628482A1 (en) * 2022-11-28 2025-10-08 Unimatec Co., Ltd. Fluorine-containing pyridone compound and method for producing same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
HUP0203160A3 (en) * 1999-11-05 2006-02-28 Warner Lambert Co Prevention of plaque rupture by acat inhibitors
WO2003090746A1 (en) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2008146259A2 (en) 2007-06-01 2008-12-04 University Of Lausanne Malt1 specific cleavage in assay and screening method
US8309523B2 (en) * 2007-11-21 2012-11-13 Vib Vzw Inhibitors of MALT1 proteolytic activity and uses thereof
WO2013013816A1 (en) * 2011-07-26 2013-01-31 Grünenthal GmbH Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
TR201903280T4 (tr) 2011-08-02 2019-04-22 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Malt1 proteazının fenotiazin türevleri ile selektif inhibisyonu.
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
EA201590916A1 (ru) 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
ES2909438T3 (es) 2013-06-26 2022-05-06 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Enantiómero (S) de mepacina como inhibidor de paracaspasa (MALT1) para tratar cáncer
EP3097124B1 (en) 2014-01-21 2018-12-19 Helmholtz Zentrum München Means and methods for detecting activated malt1
SG11201607895PA (en) 2014-05-28 2016-12-29 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
DE102015210224A1 (de) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf Neuer wirkstoff zur behandlung von krebs
US10711036B2 (en) 2015-08-28 2020-07-14 Cornell University MALT1 inhibitors and uses thereof
WO2017057695A1 (ja) 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
AU2016352813B2 (en) 2015-11-13 2019-09-19 Novartis Ag Novel pyrazolo pyrimidine derivatives
WO2018165385A1 (en) * 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof

Also Published As

Publication number Publication date
RU2019104890A (ru) 2020-08-31
US20190275012A9 (en) 2019-09-12
PE20190656A1 (es) 2019-05-08
CA3032334A1 (en) 2018-02-01
SG11201900745VA (en) 2019-02-27
CN110312724A (zh) 2019-10-08
PH12019500214A1 (en) 2019-10-28
AU2017302182B2 (en) 2021-11-04
US20190160045A1 (en) 2019-05-30
KR20190033607A (ko) 2019-03-29
JP2019522035A (ja) 2019-08-08
IL289474A (en) 2022-02-01
RU2019104890A3 (es) 2020-08-31
DOP2019000020A (es) 2019-04-30
MX2019001132A (es) 2019-12-16
WO2018020474A1 (en) 2018-02-01
AU2017302182A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1121850T1 (el) Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2019000266A1 (es) Composición de cannabis.
UA124347C2 (uk) Циклічна динуклеотидна сполука
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
CO2017011484A2 (es) Inhibidores de bromodominio
MX2019009653A (es) Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos.
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CL2019002240A1 (es) Dendrímeros terapéuticos.
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
MX387726B (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1